Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 1;4(9):e2126344.
doi: 10.1001/jamanetworkopen.2021.26344.

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Amandine Le Bourgeois  1 , Marianne Coste-Burel  2 , Thierry Guillaume  1   3 , Pierre Peterlin  1 , Alice Garnier  1 , Marie C Béné  3   4 , Patrice Chevallier  1   3
Affiliations

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Amandine Le Bourgeois et al. JAMA Netw Open. .

Abstract

This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Chevallier reported receiving honoraria from Pfizer outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Anti–SARS-CoV-2 Titers After the First and Second Vaccine Injections
Box plots show anti–SARS-CoV-2 spike protein receptor titers after the first and the second vaccine injections. Lines within boxes denote medians, error bars denote 95% CIs, circles denote data for individual patients. Comparisons are between patients for whom follow-up after allogeneic hematopoietic stem cell transplant was less than 1 year vs between 1 and 2 years vs more than 2 years.
See this image and copyright information in PMC

Comment in

References

    1. García-Suárez J, de la Cruz J, Cedillo Á, et al. ; Asociación Madrileña de Hematología y Hemoterapia (AMHH) . Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13(1):133. doi:10.1186/s13045-020-00970-7 - DOI - PMC - PubMed
    1. Xhaard A, Xhaard C, D’Aveni M, et al. . Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. Br J Haematol. 2021;192(5):e121-e124. doi:10.1111/bjh.17260 - DOI - PMC - PubMed
    1. Walsh EE, Frenck RW Jr, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 - DOI - PMC - PubMed
    1. Chevallier P, Coste-Burel M, Le Bourgeois A, et al. . Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. EJHaem. Published online June 1, 2021. doi:10.1002/jha2.242 - DOI - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. . Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489 - DOI - PMC - PubMed